Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;202(1):e1-e2.
doi: 10.1111/bjh.18755. Epub 2023 Mar 14.

Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?

Ghulam Rehman Mohyuddin  1 , Rohan Kapur  2 , Luciano Costa  3
Affiliations

Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?

Ghulam Rehman Mohyuddin et al. Br J Haematol. 2023 Jul.
No abstract available

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Mailankody S, Landgren O. T-cell engagers - modern immune-based therapies for multiple myeloma. N Engl J Med. 2022;387(6):558-61. https://doi.org/10.1056/NEJMe2209692
    1. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-75. https://doi.org/10.1038/s41375-019-0435-7
    1. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. https://doi.org/10.1056/NEJMoa2203478
    1. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-45. https://doi.org/10.1182/blood.2020005288
    1. Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901-12. https://doi.org/10.1200/JCO.21.01935

LinkOut - more resources